Clover Health Investments, Corp. (Nasdaq: CLOV) has announced changes to its Board of Directors, with Lee A. Shapiro not standing for re-election at the 2025 Annual Shareholders’ Meeting. Thomas L. Tran will take on the role of Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, succeeding Mr. Shapiro. Mr. Shapiro, who has served on the board for four years, will step down from his role on June 10, 2025.
In the wake of these changes, Thomas L. Tran, a current member of the Audit Committee, will be appointed as the new Chairman of the Audit Committee and as a member and Chairman of the Nominating and Corporate Governance Committee effective June 10, 2025.
Clover Health, a physician enablement technology company, is committed to providing access to quality healthcare to everyone on Medicare, particularly seniors who have historically lacked such access. The company’s strategy is driven by its software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease.
The company offers PPO and HMO Medicare Advantage plans in several states, with a focus on wide-network, high-choice PPO plans. Additionally, through its subsidiary, Counterpart Health, Clover Health extends the benefits of its data-driven technology platform to a wider audience of healthcare providers outside its Medicare Advantage plan, aiming to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale.
Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease. Today the company's shares have moved 2.5% to a price of $3.46. For the full picture, make sure to review Clover Health Investments,'s 8-K report.
